Probatebeta
Target

PPARA

Peroxisome proliferator-activated receptor alpha

As of the edition of 20 October 2026, PPARA (peroxisome proliferator-activated receptor alpha, UniProt Q07869) has 25 drugs tested at it and 26 companies on the list, 5 on route A and 6 on route B.

Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.

The protein

UniProt
Q07869
How well studied
Drug target: an approved drug acts on it
Where it sits in the cell
Inside the cell
Solved structures
79
Disease areas
Nutrition and metabolism; Hormones; Digestive system; Heart and blood vessels; Urinary and reproductive; Inherited and neonatal; Pregnancy and women's health; Immune system
Registered trials of its drugs
354

Drugs at this target

StatusCount
Marketed9
Active3
Went quiet6
Stopped6
Status not established1
Total25
DrugStatusFurthest phaseUS protection
FenofibrateMarketedPhase 4none listed
GemfibrozilMarketedPhase 4none listed
Fenofibric acidMarketedPhase 4none listed
AleglitazarStoppedPhase 3none listed
ElafibranorMarketedPhase 3Ends 2031
SaroglitazarMarketedPhase 4none listed
BezafibrateMarketedPhase 4none listed
ChiglitazarActivePhase 3none listed
K-877StoppedPhase 3none listed
TesaglitazarStoppedPhase 3none listed
MK-0767StoppedPhase 3none listed
ImiglitazarStoppedPhase 3none listed

12 of 25 drugs, the most tested first.

Companies at this target

Where the company standsCompanies
Route A5
Route B6
Engaged11
Undetermined4
Total on the list26
Three companies on route A or B, with the route only
CompanyRoute
SanofiRoute B
Merck & Co.Route A
AstraZenecaRoute A

The other 23 companies at PPARA

In the product

26 companies in all; 23 are not named here, and no score is.

See the 26 companies at PPARA, ranked, with the facts behind eachRequest access. Nothing is shown until you do.

More drugs at PPARA

Other targets in nutrition and metabolism

Companies holding approvals at PPARA